AANP PMHNP Certification Practice Exam V2 2026/2027 | Psychiatric Mental Health NP Certification Exam Prep | Practice Questions & Answers

AANP PMHNP Certification Practice Exam
V2 2026/2027 | Psychiatric Mental Health NP
Certification Exam Prep | Practice Questions
& Answers
AANP PMHNP CERTIFICATION PRACTICE EXAM V2 2026/2027

Psychiatric Mental Health NP Certification Exam Preparation



DOCUMENT OVERVIEW

• This comprehensive 200-question practice exam is designed to prepare
candidates for the AANP PMHNP certification by covering all major clinical domains
including mood disorders, anxiety disorders, psychotic disorders, substance abuse,
ADHD, personality disorders, neurocognitive disorders, and psychopharmacology.

• Study this material by reviewing each question carefully, attempting to answer
before reviewing the correct answer and detailed rationale, and using incorrect
responses as learning opportunities to strengthen knowledge gaps in psychiatric
assessment, diagnosis, and evidence-based treatment approaches.




QUESTIONS



QUESTION 1:

A 35-year-old female presents with depressed mood, anhedonia, fatigue,
insomnia, guilt, and difficulty concentrating for the past 3 weeks. Which of
the following is the most appropriate first-line pharmacological intervention?

A) Phenelzine

B) Fluoxetine

C) Bupropion

D) Tranylcypromine

,E) Quetiapine

CORRECT ANSWER: B) Fluoxetine

Rationale: Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine are
considered first-line agents for major depressive disorder due to their efficacy,
tolerability, and favorable side effect profile. SSRIs are preferred over MAOIs
(phenelzine, tranylcypromine) which require dietary restrictions and have
significant drug interactions, and over atypical antipsychotics (quetiapine) which are
not first-line monotherapy. Bupropion, while effective, is typically reserved for
depression with fatigue or as augmentation therapy.



QUESTION 2:

A 28-year-old male with bipolar I disorder has been on lithium for 6 months
with good mood stabilization. His recent lithium level is 0.9 mEq/L. He reports
new-onset polyuria and polydipsia. What is the most likely diagnosis?

A) Lithium toxicity

B) Nephrogenic diabetes insipidus

C) Central diabetes insipidus

D) Hyperglycemia

E) Hypothyroidism

CORRECT ANSWER: B) Nephrogenic diabetes insipidus

Rationale: Chronic lithium use causes nephrogenic diabetes insipidus in
approximately 20-40% of patients, resulting in polyuria and polydipsia despite
therapeutic lithium levels (0.6-1.2 mEq/L). This occurs due to lithium's effect on the
collecting duct's response to ADH. Lithium toxicity would present with higher serum
levels and neurological symptoms. Central diabetes insipidus is not associated with
lithium. Hyperglycemia and hypothyroidism are other lithium side effects but do
not explain the polyuria/polydipsia combination.

,QUESTION 3:

A 42-year-old woman with generalized anxiety disorder reports persistent
worry, muscle tension, and sleep disturbance despite being on sertraline 100
mg daily for 8 weeks. What is the most appropriate next step?

A) Increase sertraline to 150 mg

B) Add buspirone 15 mg daily

C) Switch to paroxetine

D) Discontinue sertraline and start lorazepam

E) Add hydroxyzine 25 mg twice daily

CORRECT ANSWER: B) Add buspirone 15 mg daily

Rationale: When SSRIs provide partial response or inadequate relief in GAD,
augmentation with buspiron (an azapirone anxiolytic) is an evidence-based strategy
that does not carry addiction risks. Buspiron is effective for GAD and can be added
to ongoing SSRI therapy. Increasing SSRI beyond 8 weeks may be premature as
some response is occurring. Switching SSRIs is less supported by evidence than
augmentation. Adding benzodiazepines (lorazepam) carries significant abuse
potential. Hydroxyzine may cause sedation and is typically second-line.



QUESTION 4:

A 19-year-old male with first-episode psychosis presents with auditory
hallucinations and paranoid delusions. His initial risperidone level is 0 mg/mL
(untreated). Which antipsychotic is most appropriate as first-line
monotherapy?

A) Haloperidol

B) Risperidone

C) Paliperidone

D) Aripiprazole

, E) Chlorpromazine

CORRECT ANSWER: B) Risperidone

Rationale: Second-generation (atypical) antipsychotics like risperidone are now
first-line for first-episode psychosis due to superior efficacy in treating negative
symptoms and reduced extrapyramidal side effects compared to first-generation
agents like haloperidol and chlorpromazine. Risperidone, paliperidone, and
aripiprazole are all appropriate second-generation options, but risperidone has the
most extensive evidence base in first-episode psychosis. Paliperidone is the active
metabolite of risperidone and would be equally appropriate. Aripiprazole is also
first-line but requires dosage consideration for optimal response.



QUESTION 5:

A 55-year-old male with chronic schizophrenia on olanzapine 15 mg daily
presents with fasting glucose of 128 mg/dL, triglycerides 250 mg/dL, and
weight gain of 8 kg over 6 months. Which intervention is most appropriate?

A) Continue olanzapine and refer to endocrinology

B) Switch to aripiprazole

C) Add metformin

D) Reduce olanzapine dose

E) Add sitagliptin

CORRECT ANSWER: B) Switch to aripiprazole

Rationale: Olanzapine has the highest propensity for weight gain and metabolic
complications among atypical antipsychotics. When a patient develops significant
weight gain and metabolic abnormalities on olanzapine, switching to an
antipsychotic with lower metabolic liability such as aripiprazole (which has minimal
weight gain and metabolic effects) is the most appropriate intervention. While
metformin or endocrinology referral may have supporting roles, switching
antipsychotics addresses the root cause. Dose reduction may compromise
psychiatric stability.